藍豐生化(002513.SZ):擬以貨幣資金、應收債權等其他非貨幣資產作價對寧夏藍豐增資不超3億元
格隆匯9月22日丨藍豐生化(002513.SZ)公佈,鑑於公司全資子公司寧夏藍豐精細化工有限公司(簡稱“寧夏藍豐”)長期淨資產為負,且公司對寧夏藍豐預付賬款餘額較大,導致其業務發展受到制約,融資渠道不暢。為了優化寧夏藍豐的資產負債結構,支持寧夏藍豐的經營發展,公司擬以貨幣資金、應收債權等其他非貨幣資產作價對寧夏藍豐進行增資,增資金額不超過3億元,其中,2000萬元計入實收資本,剩餘部分計入資本公積,本次增資完成後,寧夏藍豐注冊資本由58,000萬元增至60,000萬元,仍為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.